SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Hot Topics > Pipelines

Biopharmaceuticals becoming big business

Pipelines

As pharmas evolve into biopharmas drug company pipelines fill with biopharmaceutical products. Here we will track the latest developments, discoveries and products.

Kite inks Chinese JV and Japanese partnership for lead T Cell candidate

10-Jan-2017 - Kite Pharma has formed a joint venture with Shanghai Fosun Pharmaceutical Industrial Development Company to develop and manufacture its cell therapy axicabtagene ciloleucel in the Chinese market.

Orchard picks PharmaCell to make its autologous cell therapies

09-Jan-2017 - Orchard Therapeutics has selected Dutch CMO PharmaCell to manufacture products from its gene therapy pipeline.

Shire selling Baxalta site in Austria once earmarked to make hemophilia drug

06-Jan-2017 - Shire has confirmed it is selling a former Baxalta manufacturing site in Austria once earmarked for a €138m ($145m) expansion and modernisation.

Prokarium and Probiomed team to scale-up thermostable oral vaccine

04-Jan-2017 - The project funded by the UK and Mexican governments will look to prove the scalability of Prokarium’s oral vaccine platform, the firm says.

Humira biosimilar developers: can you find who's taking on AbbVie?

23-Dec-2016 - Over 30 companies are looking to compete against Abbvie in the adalimumab space. Can you find them all in our word search?

GSK extends single-use purification tech R&D deal with Puridify

06-Dec-2016 - The development partnership has been extended as GlaxoSmithKline looks to make clinical trial scale batches using Puridify’s Protein A alternative to packed bed chromatography columns.

Cook and Asymptote to launch water-free automated cell thawing tech

30-Nov-2016 - An automated system co-developed with Cook Regenetec offers a more controlled and repeatable method of thawing cell and gene therapies than traditional techniques, says Asymptote.

Thermo Fisher buys MTI-GlobalStem upping stem cell and reagent offering

30-Nov-2016 - Thermo Fisher has bolstered its stem cell technology and reagent business through the acquisition of MTI-GlobalStem.

WuXi to make Prima proteins from new 28,000L single-use facility in China

29-Nov-2016 - WuXi Biologics will make a recombinant soluble LAG-3 protein on behalf of Prima Biomed from its 28,000L single-use facility in China set to open next year.

Pfizer axes parts of $425m Irish expansion after dropping PCSK9 inhibitor

28-Nov-2016 - Plans to build a five-story biomanufacturing plant in Ireland could be shelved following the clinical failure of Pfizer's proposed cholesterol-lowering candidate bococizumab.

BMS biologics-focus trimmed network from 27 to 16 sites since 2007

18-Nov-2016 - Bristol-Myers Squibb has shaped its manufacturing network to support a pipeline consisting of around 75% biological products, the firm says.

uniQure to axe jobs and consolidate operations in cost-saving measures

16-Nov-2016 - Gene therapy firm uniQure will consolidate its global manufacturing and cut up to 60 jobs in a bid to recue operating expenses.

Cell Medica and Baylor extend partnership for off-the-shelf T Cells

15-Nov-2016 - Baylor College of Medicine has extended a partnership to develop off-the-shelf allogeneic cell therapies for Cell Medica.

Selexis and Xencor enter strategic agreement for cell line development

09-Nov-2016 - Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development

Sale speculation: We assess German Merck's biosimilar business

04-Nov-2016 - Germany’s Merck has refused to comment on rumours it is looking to sell its biosimilars business, but what would a hypothetical buyer actually get?

Shire closing US plant as it begins to assess post-Baxalta manufacturing footprint

04-Nov-2016 - Shire says it is closing a plasma fractionating facility in Los Angeles, US but remains positive it can successfully manage its post-Baxalta manufacturing network of 17 sites.

FIRM looks to fix blips in Japan’s fast-track regenerative medicine system

14-Oct-2016 - Japan’s early approval process for cell and gene therapies still suffers from clinical recruitment challenges and a solid manufacturing framework, says regenerative medicine group FIRM.

EpimAb and Kymab join forces to develop bispecific Abs

11-Oct-2016 - EpimAb Biotherapeutics will combine its bispecific antibody generating technology with Kymab’s mouse mAb production platform in a cross-licensing deal between the two firms.

Dispatches from CPhI Worldwide

Single-use tech will impact the 'extremely consolidated' bio-CMO space, expert

06-Oct-2016 - Lonza and Boehringer-Ingelheim dominate the consolidated biologics CMO space but disposable technologies and improved yields are beginning to change this, says PharmSource’s Jim Miller.

Bluebird gene therapy granted EMA accelerated assessment status

27-Sep-2016 - Bluebird Bio’s beta thalassemia gene therapy LentiGlobin has been accepted into the EMA’s priority review programme, PRIME.

Cell and gene therapy investment to continue to grow post-Brexit, CGT Catapult

21-Sep-2016 - Brexit will not stifle interest in the UK’s cell and gene therapy space, says the CGT Catapult which has reported a tenfold growth in investment since 2012 to £400m ($520m).

Looking for a single-use modular biologics plant in Ireland? Talk to GE

20-Sep-2016 - GE Healthcare is in discussions with companies looking to buy four fully-equipped ‘off-the-shelf’ facilities as part of a €150m investment into a biomanufacturing campus in Ireland.

Feature

Promising Korea? CMO giant Samsung Biologics opens doors to Biopharma-Reporter

16-Sep-2016 - Since 2011, Samsung Biologics has built two plants, gained Bristol-Myers Squibb and Roche as clients and launched an IPO. With a third facility under construction, Biopharma-Reporter visited to see the...

Selexis to triple cell line capacity on back of increased demand

13-Sep-2016 - Mammalian cell line developer Selexis has signed a fourth licensing agreement in as many months and is planning a "major expansion" early next year ahead of anticipated demand....

BioInvent wins antibody contract extension, talks 1,000L facility expansion

06-Sep-2016 - Swedish antibody developer BioInvent is growing its capabilities and has extended a contract with an undisclosed Big Pharma firm.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...